Quince Therapeutics advances Ataxia-Telangiectasia treatment with innovative AIDE platform, insider support, and NEAT Phase 3 trial data expected early 2026.

Ataxia-telangiectasia is a rare, inherited disease. The disease affects the nervous and immune systems. Young children typically have symptoms before age 5 including ataxia (trouble coordinating ...

Ataxia-telangiectasia (A-T) is a progressive genetic disorder affecting the central nervous and immune systems, and involving chromosomal instability, cancer predisposition, radiation sensitivity ...

The patients with ataxia telangiectasia were inadvertently tested with 500 units of streptokinase-streptodornase — this dose produces large, painful, indurated lesions in all normal persons.

Ataxia telangiectasia develops in childhood, and symptoms of the inherited multisystem disorder include ataxia, oculomotor apraxia, and involuntary movements.

Ataxia-telangiectasia (A-T) was first described over 80 years ago. Since the discovery of the A-T mutated (ATM) protein, which is defective in A-T, rapid progress has been made regarding how ATM ...

New research lends insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia. Ataxia telangiectasia (A-T) is a rare, genetic immunodeficiency disease that affects multiple organ ...

Ataxia-telangiectasia – this is a rare type of hereditary ataxia and is seen in 1 in 100,000 babies. Symptoms usually begin in early childhood and progressively worsen with age.

The event benefits families and patients with the genetic disease ataxia-telangiectasia (AT). "Ataxia" refers to poor muscle control, causing clumsy or compromised walking/muscle movements.

A local company provided a creative solution for an Omaha child who has been diagnosed with Ataxia-telangiectasia, a rare neurodegenerative disorder that causes poor coordination.

The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit in the rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo.

Wheelchair dependence in patients with the classic type of ataxia telangiectasia -- accounting for upwards of 80% of individuals with the condition -- occurs at a median of age 10.